We’re pleased to share an important milestone in our sustainability journey.

ExSyn has been awarded the EcoVadis Platinum Medal, placing us among the top 1% of companies globally evaluated for environmental, social and ethical performance.

This recognition, achieved in our first assessment, reflects our strong focus on responsible business practices.

From strengthening compliance frameworks to advancing sustainable procurement and operations, we remain committed to building a transparent and sustainable value chain.

We thank our customers, suppliers and partners for their continued trust and support.

Warm regards,
The ExSyn Team

READ MORE
Exim rebrands as ExSyn: We celebrate our 30-year heritage with a new brand and website that bring alive our values and purpose
News · 27/03/2021

Today we announce that Exim is rebranding as ExSyn. We are presenting a new brand identity and website as a reflection of our relentless transformation over the course of 30 years serving the pharma and chemical industries. The new brand builds upon our core strengths as a sourcing company and captures our most essential duty: helping improve people’s health and lives.

In focus: Trichloroacetonitrile
Products in focus · 09/06/2026

Trichloroacetonitrile is a halogenated organic compound belonging to nitrile family. Its strong electrophilic character makes it a valuable intermediate in organic synthesis. It readily undergoes hydrolysis, particularly under acidic or basic conditions, yielding trichloroacetamide and related derivatives.

EU & US Move to Phase Out Animal Testing
News · 05/06/2026

In a converging policy shift on both sides of the Atlantic, European regulators this week published a roadmap toward fully replacing animal testing for chemical safety assessments, while the US Environmental Protection Agency issued a rare update to its list of alternative test methods.

Global Pharma Fine Chemicals: Compliance & Localisation
News · 02/06/2026

The global pharmaceutical fine chemicals sector is undergoing a profound transformation, with India emerging as a central growth engine amid sweeping changes in supply chain strategies and regulatory priorities. As drug makers and contract manufacturers adapt to stricter oversight and evolving sourcing preferences, the industry’s focus is shifting rapidly from cost efficiency to compliance, localisation and technical sophistication.